Skip to main content

Table 2 Fluid content, blood flow, cardiac function, and circulatory function at baseline and at study end in the two groups

From: Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial

Variable

Placebo (n = 15)

Dapagliflozin (n = 15)

p*

Baseline

12 weeks

Change

p

Baseline

12 weeks

Change

p

HR (beats/min)

68.6 (67.4; 78.3)

72.4 (66.9; 76.3)

− 0.9 (− 4.4; 5.0)

0.91

66.3 (61.1; 79.6)

69.6 (64.1; 81.2)

2.0 (− 3.1; 4.6)

0.39

0.53

SBP (mmHg)

129.0 (118.9; 135.6)

126.0 (118.1; 136.7)

2.47 (− 9.3; 6.0)

0.84

141.9 (133.4; 152.7)

136.3 (130.1; 147.3)

− 7.40 (− 8.9; 1.5)

0.03

0.04

DBP (mmHg)

76.1 (71.8; 81.4)

77.7 (73.9; 82.1)

2.3 (− 2.4; 4.6)

0.31

81.9 (75.4; 87.5)

82.0 (75.4; 84.7)

− 2.6 (− 3.8; 4.6)

0.91

0.32

SV (mL)

98.9 (72.3; 113.6)

85.7 (78.9; 100.8)

− 2.1 (− 16.6; 7.0)

0.33

94.8 (81.2; 104.0)

84.8 (70.3; 109.9)

− 7.8 (− 16.6; 14.4)

0.50

0.92

SI (mL/m2)

48.0 (36.7; 51.7)

42.9 (39.3; 44.7)

− 1.2 (− 8.2; 3.4)

0.43

47.1 (38.7; 56.3)

46.6 (39.2; 53.1)

− 3.3 (− 8.2; 7.4)

0.61

0.76

CO (L/min)

6.63 (5.42; 7.97)

6.31 (4.71; 7.98)

− 0.45 (− 0.79; 0.58)

0.46

6.94 (5.62; 7.81)

5.98 (5.52; 7.81)

− 0.49 (− 0.85; 1.06)

0.87

0.49

CI (L/min/m2)

3.33 (2.86; 3.62)

3.28 (2.47; 3.54)

− 0.21 (− 0.38; 0.29)

0.50

3.49 (2.86; 3.79)

3.45 (2.98; 3.66)

− 0.23 (− 0.37; 0.55)

0.82

0.52

EF (%)

65.6 (60.8; 69.0)

65.8 (62.3; 67.8)

0.6 (− 1.3; 4.4)

0.26

66.9 (61.5; 69.9)

65.6 (60.4; 69.6)

− 0.3 (− 4.4; 2.8)

0.43

0.19

AI (/100/s2)

47.6 (30.8; 53.6)

43.1 (36.1; 50.9)

− 0.1 (− 5.8; 4.2)

0.65

55.6 (39.8; 70.9)

58.6 (41.2; 65.4)

− 2.9 (− 10.2; 5.4)

0.39

0.85

VI (/1000/s)

33.1 (25.6; 42.4)

29.9 (25.7; 40.5)

− 4.1 (− 6.4; 2.4)

0.17

42.1 (35.4; 45.9)

43.6 (31.6; 49.0)

1.7 (− 3.0; 4.7)

0.69

0.18

STR

0.29 (0.24; 0.37)

0.28 (0.25; 0.34)

− 0.01 (− 0.07; 0.02)

0.22

0.27 (0.22; 0.35)

0.29 (0.23; 0.37)

0.00 (− 0.05; 0.07)

0.43

0.18

LVET (ms)

322.9 (311.7; 347.1)

330.0 (300.0; 364.8)

6.6 (− 10.4; 24.9)

0.57

337.0 (294.6; 376.6)

324.3 (298.8; 359.2)

1.8 (− 31.2; 17.4)

0.91

0.72

LCW (kg/min)

7.09 (6.18; 9.74)

6.71 (5.59; 9.50)

− 0.16 (− 0.48; 0.52)

0.89

9.30 (6.57; 9.82)

7.50 (6.54; 9.68)

0.44 (− 0.92; 1.05)

0.96

0.85

LCWI (kg × min × m−2)

3.66 (3.20; 4.37)

3.53 (2.90; 4.32)

− 0.08 (− 0.22; 0.26)

0.98

4.48 (3.37; 4.58)

4.12 (3.49; 4.93)

0.23 (− 0.45; 0.57)

0.82

0.77

SVR (dyne × s × cm−5)

924.0 (878.9; 1326.9)

1030.9 (904.3; 1374.6)

109.7 (− 76.6; 185.0)

0.36

1116.0 (965.8; 1358.8)

1157.3 (962.1; 1394.8)

81.1 (− 190.5; 174.4)

0.96

0.60

SVRI (dyne × s × cm−5 × m−2)

2051.9 (1770.6; 2581.4)

2119.0 (1887.7; 2672.8)

151.7 (− 150.86; 391.7)

0.39

2162.1 (1953.4; 2494.4)

2037.5 (1971.8; 2557.1)

150.7 (− 437.4; 310.5)

0.61

0.58

TFC (k/Ohm)

33.4 (29.0; 37.3)

29.9 (27.7; 34.9)

− 0.86 (− 3.5; 0.6)

0.16

31.4 (28.9; 35.1)

31.6 (29.4; 36.3)

− 0.8 (− 1.6; 1.6)

0.82

0.47

TFCI (k/Ohm/m2)

15.2 (13.5; 17.9)

14.5 (12.8; 17.7)

− 0.3 (− 1.0; 0.2)

0.28

15.7 (14.9; 17.6)

15.6 (14.8; 18.1)

0.0 (− 0.5; 0.4)

0.86

0.35

TAC (mL/mmHg)

2.19 (1.65; 2.31)

1.83 (1.38; 2.65)

0.00 (− 0.39; 0.29)

0.70

1.95 (1.2; 2.22)

1.60 (1.19; 2.22)

0.00 (− 0.20; 0.19)

1.00

0.95

TACI (mL/mmHg/m2)

1.03 (0.78; 1.07)

0.91 (0.71; 1.17)

0.00 (− 0.18; 0.16)

0.84

0.97 (0.72; 1.06)

0.80 (0.68; 1.07)

0.00 (− 0.09; 0.11)

0.88

0.97

  1. Data are expressed as median (interquartile range)
  2. * p-values of comparison between changes observed in dapagliflozin group versus those in placebo group
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840